Drug giant Eli Lilly says ... "It's a weight loss drug, but it's probably more than that," he said, citing heart disease and diabetes, for which the drugs are already approved, and potentially ...

Those results helped the drug receive its Food and Drug Administration approval for weight loss last year. Eli Lilly submitted data for tirzepatide as a treatment for moderate-to-severe ...

Zepbound only received Food and Drug Administration approval for chronic weight management last November. Lilly’s products ... the past year for their weight loss as well as cardiovascular ...

Starter doses of the weight-loss drug Zepbound are ... Patients “should not use a compounded drug if an approved drug is available,” the agency has said. Eli Lilly has also raised concerns ...

Eli Lilly’s weight-loss drug, Zepbound ... The data at that time showed the drug helped cut weight significantly in obese patients, helping it to secure US regulatory approval. It was unclear if the ...

Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss ... of drugs called GLP-1 agonists, which help regulate blood sugar and appetite. They were initially approved for ...

The drugs also prompted significant weight loss: on average, 12-23% of body weight. First, these new injectable drugs were meant to treat diabetes. Then, they became approved for weight loss.

"When FDA-approved medicines are ... surging demand for Lilly and Danish rival Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drugs, which can cost more than $1,000 for a month's supply ...

Aug 20 (Reuters) - Eli Lilly's (LLY.N), opens new tab weight-loss drug ... showed the drug helped cut weight significantly in obese patients, helping it to secure U.S. regulatory approval.